- Home
- GILD vs SPGI Comparison
GILD vs SPGI Comparison
Compare GILD & SPGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GILD | SPGI |
|---|---|---|
| Founded | 1987 | 1860 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 184.4B | 160.5B |
| IPO Year | 2001 | 1994 |
Fundamental Metrics
Financial Performance| Metric | GILD | SPGI |
|---|---|---|
| Price | $139.94 | $434.38 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 18 | 15 |
| Target Price | $146.50 | ★ $567.73 |
| AVG Volume (30 Days) | ★ 4.9M | 1.8M |
| Earning Date | 04-23-2026 | 04-28-2026 |
| Dividend Yield | ★ 2.34% | 0.89% |
| EPS Growth | ★ 1684.21 | 18.70 |
| EPS | 6.78 | ★ 14.66 |
| Revenue | ★ $24,689,000,000.00 | $6,063,000,000.00 |
| Revenue This Year | $4.65 | $9.70 |
| Revenue Next Year | $5.96 | $7.37 |
| P/E Ratio | ★ $20.66 | $29.58 |
| Revenue Growth | ★ 9.98 | 7.10 |
| 52 Week Low | $95.30 | $381.61 |
| 52 Week High | $157.29 | $579.05 |
Technical Indicators
Market Signals| Indicator | GILD | SPGI |
|---|---|---|
| Relative Strength Index (RSI) | 47.28 | 52.69 |
| Support Level | $108.90 | $401.95 |
| Resistance Level | $149.38 | $451.66 |
| Average True Range (ATR) | 3.30 | 9.49 |
| MACD | 0.04 | 2.82 |
| Stochastic Oscillator | 48.48 | 92.71 |
Price Performance
Historical ComparisonAbout GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About SPGI S&P Global Inc.
S&P Global provides data and benchmarks to capital and commodity market participants. Its ratings business is the largest credit rating agency in the world and S&P's largest segment by profitability. S&P's largest segment by revenue is market intelligence, which provides desktop, data and advisory solutions, enterprise solutions, and credit/risk solutions mostly in the financial-services industry. S&P's other segments include commodity insights (Platts and other data), mobility (Carfax), and indexes.